The assays currently offered are based on human or animal cells transfected to express single or dual human kidney transporters on their surfaces. The major limitation is that they…
Read updateNewcells Biotech has joined the StemBANCC project, a pan-EU consortium made up of major pharmaceutical and academe groups. StemBANCC’s goal is to generate 1,500 iPSC lines from 500 people,…
Read updateThe in3 project is funded by the EU’s Marie Skłodowska-Curie Action – Innovative Training Network (MSCA-ITN), part of a 3-year project to develop novel ways to assess toxicity for…
Read updateWorking with academics Prof Mark Birch-Machin and Dr Peter Hanson from the Institute of Cellular Medicine, Newcells is using its expertise in cellular reprogramming and differentiation of iPSCs to…
Read updateThe agreement will enable Newcells to develop, manufacture, distribute products and offer services to customers based on reprogramming cells using the CytioTuneTM-iPS kit. Prof Lyle Armstrong, CSO of Newcells Biotech,…
Read updateThe agreement will enable Newcells to develop, manufacture, distribute products and offer services to customers in the pharmaceutical, biotechnology and academic sectors in Europe. Dr Mike Nicholds CEO of Newcells…
Read update